Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers
Better collaboration between community and academic cancer centers could benefit patients.
The model was developed using machine learning techniques and programmed with data from a Danish cancer registry.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
The majority of patients studied who stopped TKI therapy remained treatment-free at 3 years.
In the immunotherapy era, the optimal setting and sequencing of BRAF+MEK inhibition remains unresolved.
Genomic and proteomic studies of medulloblastoma samples helped researchers characterize new cancer subtypes and targets.
Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.
Image-guided microwave ablation of early-stage renal tumors shows promise but a new retrospective study from the Mayo Clinic found some cases of major bleeding.
Immune checkpoint inhibitor pneumonitis is a potentially serious complication that may occur more in patients with lung cancer than previously suspected.
Cost-effectiveness of TKIs for CML treatment is a complex topic that requires consideration of multiple factors — not just apparent costs to payers.
Tackling EBV-Associated Lymphoma: Early Research Finds Overall Survival Benefit After Donor Transplants
Use of experimental T cells that target Epstein-Barr virus proteins in relapsed or refractory lymphoma may improve overall survival.
A draft guideline from the National Consensus Project for Quality Palliative Care describes best practices for caring for individuals who are seriously ill.
Utilizing data from the PREVAIL dataset, researchers developed mathematical models that can provide prognostic information for men being treated with enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer.
Omega-3 fatty acids found in fish oil act through a host receptor, GPR120, to confer anti-prostate cancer effects. Additional studies are underway.
A change in diagnosis was often the result of review by a multidisciplinary tumor board at the NCI-designated cancer center.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Moving Targets: Off-Label Prescribing of Targeted Therapies
- New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma
- 2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
- Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer
- Immunotherapy Combo in Head and Neck Cancer Shows Activity in Phase 2 Trial
- Nutraceuticals/Supplements and Cancer Prevention: All Hype?
- Plastics and Cancer
- Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition
- Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited
- POT1 Revealed as a Sarcoma Predisposition Gene
- IMRT Linked to Fewer Instances of Local Recurrence in Sarcoma: A Long-Term Follow-Up
- Study Adds More Evidence to Support Active Surveillance as the Standard of Care for Certain Desmoid Tumors
- Palliative Care and Survivorship